Dr. Michael Oliver, D.O.
Internal Medicine (Internal Medicine Physician)
Who else practices at this address →
Beaver County includes primary care (3% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Lake Erie College of Osteopathic Medicine, Erie (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 221
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Lake Erie College of Osteopathic Medicine, Erie
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
PA license OS012421
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- Heritage Valley Beaver Beaver, PA
- Heritage Valley Sewickley Sewickley, PA
Medical groups
- Heritage Valley Multispecialty Group Inc (227 clinicians)
- Mrs Physical Therapy (182 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 221
- Services billed
- 2,457
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 452 | 219 |
| Established patient office or other outpatient visit, 20-29 minutes | 72 | 53 |
| Injection of drug or substance under skin or into muscle | 52 | 15 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 35 | 35 |
| Administration of influenza virus vaccine | 32 | 32 |
| Transitional care management services for problem of at least moderate complexity | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 61 payments worth $1,203 in total to this clinician.
| GlaxoSmithKline, LLC. | $295 |
|---|---|
| Novo Nordisk Inc | $279 |
| Lilly USA, LLC | $150 |
| Otsuka America Pharmaceutical, Inc. | $125 |
| Pfizer Inc. | $62.50 |
| E.r. Squibb & Sons, L.l.c. | $33.78 |
| Amgen Inc. | $29.55 |
| Recor Medical Inc | $28.13 |
| Food and Beverage | $1,203 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 1 companies. The companies reported $1,083,960 in research payments for these studies, mostly to the institutions running them.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company · Completed · NCT06045221 - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.